

Kaunas COST Meeting

Day 0

Day 0	
17th March, 2022, Thursday	Didžioji LSMUL KK auditorija + MS Teams
8:30 – 9:00 EET 7:30 – 8:00 CET 6:30 – 7:00 UTC	Professor Guruprasad Aithal, GI & Liver Disorders Theme Lead, Professor of Hepatology, National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre: "DILI Clinical practice guidelines"

Day 1

Day 1	
18th March, 2022, Friday	Vaikų klinikos auditorija + Zoom
9:00 – 9:30 EET 8:00 – 8:30 CET 7:00 – 7:30 UTC	Registration, morning coffee
9:30 – 9:40 EET 8:30 – 8:40 CET 7:30 – 7:40 UTC	Welcome from the LOC, important information for participants online and at the venue
9:40 – 9:50 EET 8:40 – 8:50 CET 7:40 – 7:50 UTC	Welcome to PRO-EURODILINET members and guests <i>LSMULKK</i>
9:50 – 10:30 EET 8:50 – 9:30 CET 7:50 – 8:30 UTC	Lithuanian perspective: gastroenterology and hepatology, prof. Limas Kupčinskas
10:30 – 11:15 EET 9:30 – 10:15 CET 8:30 – 9:15 UTC	Reports from all WGs Leaders
11:15 – 11:45	Coffee Break
11:45 – 12:25 EET 10:45 – 11:25 CET 9:45 – 10:25 UTC	Dr. T. Hammond, WG5 and AZ: "Reactive metabolite (acyl glucuronide) toxicity"
12:30 – 14:00 EET 11:30 – 13:00 CET 10:30 – 12:00 UTC	Discussion feasibility on "Clinical Trial on DILI treatment", chaired by dr. Einar Bjornson, dr. Raul Andrade, dr. Mercedes Robles, and dr. Judith Sanabria
14:00 – 15:20	Lunch
15:30 – 17:00 EET 14:30 – 16:00 CET 13:3 – 15:00 UTC	Break out session WG 1-5
	Social Program for participants attending in person

Day 2

Day 2	
19th March, 2022, Saturday	Vaikų klinikos auditorija + Zoom
10:00 – 10:30 EET 9:00 – 9:30 CET	Registration, morning coffee

8:00 – 8:30 UTC	
10:30 – 11:15 EET 9:30 – 10:15 CET 8:30 – 9:15 UTC	Biomarker qualification: EU and US perspectives. Prof. Romaldas Maciulaitis, State Medicines Control Agency
11:15 – 12:00 EET 10:15 – 11:00 CET 9:15 – 10:00 UTC	Dr. Mercedes Robles Diaz “Prognostic and diagnostic DILI biomarkers: an analysis of Spanish DILI Registry”
12:00 – 13:30 EET 11:00 – 12:30 CET 10:00 – 11:30 UTC	Round table discussion: Regulatory decisions that can impact public health: how scientists (also in the ProEuroDILI Network) can help? The difficulties faced with the limited or incomplete information provided to make regulatory decisions. When will we validate the DILI Biomarker? Prof. Romaldas Mačiulaitis, prof. Markku Pasanen
13:30 – 14:30	Lunch
14:30 – 15:30 EET 13:30 – 14:30 CET 12:30 – 13:30 UTC	ECIs Forum (to get to know each other, possible mentors and to work collaboratively and for further developing leadership skills)
15:30 – 16:00 EET 14:30 – 15:00 CET 13:30 – 14:00 UTC	Reflections and concluding remarks
16:00 – 17:00 EET 15:00 – 16:00 CET 14:00 – 15:00 UTC	Core group meeting